CURRICULUM VITAE

Date of Revision: 02/07/2019

**Name:** Lauren Emily Cohn, M.D.

**Proposed for Promotion to:** Professor, Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Clinician Educator Track

**Current Term:** July 1, 2015 to June 30, 2020

**School:** Yale University School of Medicine

**Reason for Reappointment:**

**Education:**

B.A. Biology, Smith College, Northampton MA, 1982

M.D. University of Minnesota Medical School, Minneapolis MN, 1987

**Career/Academic Appointments:**

1987-1990 Resident in Internal Medicine, Columbia-Presbyterian Medical Center,

New York NY

1990-1991 Clinical Fellow, Pulmonary Division, Columbia University College of Physicians and Surgeons, New York NY

1990-1993 Clinical Assistant Physician, Columbia-Presbyterian Medical Center,

New York NY

1991-1993 Assistant in Clinical Medicine, Columbia University College of Physicians and Surgeons, New York NY

1991-1993 Post-Doctoral Research Fellow, Department of Medicine, Columbia University College of Physicians and Surgeons, New York NY

1993-1995 Associate Research Scientist, Yale University School of Medicine,

New Haven CT

1993-present Staff Physician, Yale-New Haven Hospital, New Haven CT

1993-present Staff Physician, V.A. Connecticut Health Care System, West Haven CT

1995-2001 Assistant Professor, Department of Internal Medicine, Section of Pulmonary & Critical Care Medicine, Yale University School of Medicine, New Haven CT

2001-2005 Associate Professor (Traditional Track), Department of Internal Medicine, Section of Pulmonary & Critical Care Medicine, Yale University School of Medicine, New Haven CT

2005-2007 Associate Clinical Professor, Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT

2007-2015 Associate Professor (Clinician-Scholar Track), Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT

2015-present Associate Professor (Clinical-Educator Track), Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT

**Administrative Positions:**

2017-present Pulmonary Clinic Director, Newington VA Hospital, V.A. Connecticut Health Care System

2015-present Co-Chair, Clinical Integration and Population Health Pulmonary Workgroup, Yale-New Haven Health System, New Haven CT

2005-present Co-Director, Yale Center for Asthma and Airway Diseases, Yale University School of Medicine, New Haven CT

1995-1998 Medical Director, Department of Respiratory Care, V.A. Connecticut Health Care System, West Haven CT

# Board Certification:

American Board of Internal Medicine, Internal Medicine, 1990

American Board of Internal Medicine, Pulmonary Diseases, 1992, 2005, 2017

# Professional Honors and Recognition:

**International/National/Regional**

2018 Alumni Achievement Award, Sarnoff Foundation

2004-2007 American Lung Association, Career Investigator Award

2000 Cystic Fibrosis Foundation, N.I.H. Award, declined

1998 NHLBI, Mentored Clinical Scientist Award, 50th Anniversary Celebration

1995 Parker B. Francis Foundation, Fellowship Award, declined

1995-2001 NIH/NHLBI, Clinical Investigator Development Award (K08)

1991-1992 Sarnoff Foundation, Sarnoff Scholar Award

1987 American Medical Women's Association, Carroll L. Birch Award

1987 University of Minnesota, J. Thomas Livermore Award for merit in the study of Hematology

1984-1985 Sarnoff Foundation, Sarnoff Fellowship

1982 Cum Laude, Smith College

**University**

2009-2010 Awardee, Yale Rheumatic Diseases Research Core Center Pilot Funding

1998-2000 Junior Faculty Research Award, Department of Internal Medicine, Yale University School of Medicine

1998 Hellman Family Fellowship, Yale University

**Grant/Clinical Trials History:**

**Current Grants**

Agency: NIH / NHLBI

I.D.# UH2 HL123876-01

Title: *Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma*

P.I.: Chupp

Role on Project: Co-Investigator

Effort: 25% (at Yale)

Direct costs per year: $ 1,255,482

Total costs for project period: $ 8,279,075.00

Project period: 09/01/14 – 08/30/19

Agency: NIH / NHLBI

I.D.# R01 HL125897

Title: *Novel Role of EGFR in Virus-Induced Asthma Exacerbations*

P.I.: Koff

Role on Project: Co-Investigator

Effort: 5% (at Yale)

Direct costs per year: $ 250,000

Total costs for project period: $ 8,279,075.00

Project period: 08/01/15 – 6/30/20

**Industry-Sponsored Clinical Research Trials** (need to update)

**Active Clinical Trials**

Agency: Boehringer-Ingelheim

Role: Principal Investigator

Trial: *Study 1311.14: A Phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 as add-on therapy over 24 weeks in patients with severe persistent asthma.*

Study: Closed.

Agency: Sanofi-Aventis

Role: Principal Investigator

Trial: *A Randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma*

Study: Closed. Extension trial ongoing.

Agency: Roche/Genentech

Role: Co-Investigator

Trial: *A Phase IIB, randomized, double-blind, placebo-controlled, multicenter, dose ranging study to assess the efficacy and safety of MSTT1041A in patients with uncontrolled severe Asthma.*

Study: Ongoing, Closed to enrollment

Agency: Pearl Therapeutics

Role: Co-Investigator

Trial: *A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects With Moderate to Very Severe COPD*

Study: Ongoing, Closed to enrollment

Agency: Roche/Genentech

Role: Co-Investigator

Trial: *A Prospective, single-arm, longitudinal, international, multicentre study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.*

Study: Closed.

Agency: GlaxoSmithKline

Role: Co-Investigator

Trial: *Phase III Study CT1116855, IMPACT: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.*

Study: Closed.

Agency: Astra-Zeneca

Role: Co-Investigator

Trial: *D3251C00003, GALETHEA, Phase III: A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 2 doses of Benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD exacerbations.*

Study: Closed.

Agency: AstraZeneca

Role: Co-Investigator

Trial: *A multicentre, randomized, double-blind, parallel group, placebo controlled, phase III efficacy and safety study of Benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting β2 agonist in patients with uncontrolled asthma (SIROCCO).*

Study: Closed. Extension trial ongoing.

Agency: Boston Scientific Corporation (BSC) and Asthmatix Inc.

HIC 1102008067

Role: Co-Investigator

Trial: *Post-FDA approval clinical trial evaluating Bronchial Thermoplasty in severe persistent asthma.*

Study: Ongoing, closed to enrollment

Agency: GlaxoSmithKline

HIC : 0810004339

Role: Co-Investigator

Trial: *Anti-IL-5 Therapy: Compassionate Use Trial*

Study: Ongoing.

Agency: GlaxoSmithKline

Role: Co-Investigator

Trial: *Phase III Study 200862: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of Mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control.*

Study: Closed. Extension trial ongoing.

**Past Grants**

Agency: Moerae Matrix, Inc.

Title: *Effects of MMI-0100 in asthma*

P.I.: L. Cohn

Effort: 5%

Direct costs per year: $ 100,000

Project period: **04/01/16 – 06/30/17**

Agency: W.W. Winchester Fund of Yale-New Haven Hospital

I.D.# Research Award

Title: *Protective Function of IFN-g via the Airway Epithelium in Mycobacterial Infection*

P.I.: Lauren Cohn

Effort: 5%

Total costs for project period: $ 100,000

Total costs for project period: $200,000

Project period: 10/01/12 - 09/30/14

Agency: NIH/NHLBI

I.D.# R01 HL 081160

Title: *Airway Inflammation-Related Inhibition of Disease (AIRID)*

P.I.: Lauren Cohn

Effort: 30%

Direct costs per year: $250,000

Total costs for project period: $2,068,021

Project period: 1/01/08 – 12/31/12

Agency: NIH/NHLBI

I.D.# U01 ES015674

Title: *Sensory Neural Mechanisms of Pulmonary Agent and Vesicant Toxicity*

P.I.: Sven Jordt

Effort: 5%

Direct costs per year: $250,000

Total costs for project period: $2,068,021

Project period: 1/01/08 – 12/31/12

Agency: Seltzer Family Translational Research Grant (Grateful Patient)

P.I.: Lauren Cohn

Total costs for project period: $55,000

Project period: 1/01/06 – 12/31/2013

Agency: NIH/NIAID

I.D.# R21 AI 083475

Title: *Immune Regulation in the Respiratory Tract by the Epithelial Protein PLUNC*

P.I.: Lauren Cohn

Effort: 5%

Total costs for project period: $455,126

Project period: 07/01/09 – 06/30/11

Agency: NIH/NHLBI

I.D.# R01 HL 64040

Title: *T Cell Control of Airway Mucus*

P.I.: Lauren Cohn

Effort: 45%

Total costs for project period: $3,379,502

Project period: 04/01/00 – 03/31/10

Agency: American Asthma Foundation

I.D.# AAF-07-0212

Title: *Sensory Chemoreceptors in Asthma and Airway Hyperresponsiveness*

P.I.: S. Jordt

Effort: 5%

Total costs for project period: $ 212,693

Project period: 07/01/10 – 06/30/11

Agency: NIH/NIAID

I.D.# P30 AR053495

Title: *Experimental Induction of Caplan's-Like Syndrome in Mice*

P.I.: Lauren Cohn

Effort: 2%

Total costs for project period: $ 55,166

Project period: 08/01/09 – 07/31/10

Agency: NIH/NHLBI

I.D.# P01 HL 56389

Title: *Initiation and Effector Mechanisms in Lung Th2 Immunity*

P.I.: J. Elias (Lauren Cohn, Core PI)

Effort: 15%

Total costs for project period: $535,000

Project period: 04/01/02 - 02/28/08

Agency: Juvenile Diabetes Research Foundation

I.D.# N/A

Title: *Inhaled Insulin and Lung Immunity*

P.I.: Lauren Cohn

Effort: 5%

Total costs for project period:

Project period: 09/01/07 – 8/31/08

Agency: American Lung Association

I.D.# C1-1280-N

Title: *Mechanisms Regulating Inhaled Tolerance Induction*

P.I.: Lauren Cohn

Effort: 30%

Total costs for project period: $150,000

Project period: 07/01/04 – 06/30/07

Agency: Millennium Pharmaceuticals Inc.

I.D.# 212742

Title: *Direct Measurement of AHR in CRTH2-Deficient Mice*

P.I.: Lauren Cohn

Effort: 2%

Total costs for project period: $16,350

Project period: 11/21/05 – 11/20/06

Agency: NIH/NHLBI

I.D.# R01 HL 54450

Title: Immunopathogenesis of Airway Inflammation

P.I.: Kim Bottomly

Effort: 0% (collaborator)

Total costs for project period: $2,142,981

Project period: 03/01/99 – 02/28/04

Agency: NIH/NHLBI

I.D.# R01 HL 60995

Title: *Virus-Infected T-Cell Differentiation in Asthma*

P.I.: Anuradha Ray

Percent effort: 5%

Total costs for project period: $1,262,292

Project period: 07/01/98 – 6/30/02

Agency: NIH/NHLBI

I.D.# P01 HL 56389

Title: *T Lymphocytes and Cytokines in Asthma*

P.I.: Jack Elias (Lauren Cohn, Core PI)

Effort: 10%

Total costs for project period: $305,747

Project period: 12/1/96 – 11/30/01

Agency: NIH/NHLBI

I.D.# K08 HL 03308

Title: *Th2 Cell Induction and Effector Function in the Airway*

P.I.: L. Cohn

Effort: 80%

Total costs for project period: $501,795

Project period: 05/01/95 – 04/30/00

Agency: Yale University – Department of Internal Medicine

I.D.# Junior Faculty Research Award

Title: *CD4 T Cell Regulation of Airway Epithelial Mucus Production*

P.I.: Lauren Cohn

Effort: 25%

Total costs for project period: $70,000

Project period: 01/01/98 – 12/31/99

Agency: 1998 Hellman Family Fellowship

I.D.# N/A

Title: CD4 T cell Subsets and Airway Inflammation in a Murine Model of Asthma

P.I.: Lauren Cohn

Effort: N/A

Total costs for project period: $25,000

Project period: 07/01/98

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:**

**International/National:**

2018: American Thoracic Society, Speaker, Research Breakthroughs from NHLBI's Centers for Advanced Diagnostic And Experimental Therapeutics Program, San Diego, CA.

*A targeted approach to asthma management*

2015: Internal Medicine Grand Rounds, Geisinger Medical Center, Danville, PA.

*Refractory Asthma: New Tools to Refine and Treat Disease.*

2014: Pulmonary Grand Rounds, Geisinger Medical Center, Danville, PA

*Severe Asthma: Novel therapies.*

2013: American Thoracic Society,Lead Discussion Facilitator, Thematic Poster Session, Pulmonary and Systemic Inflammation. Philadelphia, Pennsylvania.

2012: American Academy of Allergy Asthma and Immunology, Speaker, Orlando, FL.

*Deeper Insights into the Mechanisms of Asthma and Allergic Inflammation: Regulation of Allergic Airway Disease by IFN-gamma.*

2012: American Thoracic Society, Speaker, Post-Graduate Workshop, San Francisco, CA.

*Th2 Development And Effector Function in PULMONARY ADAPTIVE IMMUNITY: MORE THAN JUST CROSSING YOUR T’S.*

2010:Pittsburgh International Lung Conference, Moderator,Pittsburgh, PA *. Understanding the Interface Between Asthma, Host Defense and Mucosal Immunity.*

2010:American Thoracic Society, Symposium Chair*,* New Orleans, LA.

*Mucus Plugs for 2010: Update on Mucus in Airway Homeostasis and Disease*.

2010: American Thoracic Society, Speaker, Mini-symposium, New Orleans, LA.

*IFN-gamma acts on the airway epithelium to regulate allergic airway inflammation*.

2009: Keystone Symposium, Allergy and Asthma, Speaker*,* Keystone,CO.

*IFN-gamma modulates allergic airway disease through effects on the airway*

*epithelium*.

2008: AAAAI International Meeting, Seminar Leader, Philadelphia, PA.

*T Cells in Immunity, Allergic Diseases and Asthma: Latest Advances in NKT Cell and Regulatory T Cell Biology.*

2007: Pulmonary Seminar, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY.

*Immune Regulation of Airway Inflammation in Asthma.*

2007: Pulmonary Conference, Tufts University/New England Medical Center, Boston, MA. *Immune Regulation of Airway Inflammation.*

2007: Pulmonary Research Seminar, Brown University, Providence, RI.

*Airway Inflammation and Goblet Cell Metaplasia: Sorting out the Sticky Details.*

2006: Pittsburgh International Lung Conference, Speaker, Pittsburgh, PA.

*AIRID, A Novel Regulatory Pathway in the Respiratory Tract.*

2006: American Thoracic Society, Symposium Chair and Speaker, San Diego, CA. *Immunoregulation in the Respiratory Tract: AIRID, A Novel Regulatory Pathway in the Respiratory Tract.*

2006: American Thoracic Society, Symposium Chair, San Diego, CA.

*Immunoregulation in the Respiratory Tract: Initiating Respiratory Immune Responses: Knowing When To Pull the Trigger.*

2006: European Academy of Allergology and Clinical Immunology, Workshop Chair and Speaker, Vienna, Austria.

*Mechanisms of Mucus Synthesis and Secretion in Asthma: Mechanisms of Mucus*

*Induction in Allergic Inflammation in Asthma.*

2005: Medical Grand Rounds, Albert Einstein College of Medicine & Montefiore Medical Center, New York, NY

Immune Regulation in Asthma: Lessons from Animal Models.

2004: Immunology Council Lecture, Johns Hopkins University, Baltimore, MD.

*Regulation of CD4 Effector Function in the Airways.*

2004: Allergy and Clinical Immunology Research Conference, Johns Hopkins University, , Baltimore, MD.

*Immune Dysregulation in Asthma: What Contributes to Th2 Cell Persistence?*

2004: Plenary Speaker, NIH Cytokine Interest Group Symposium, National Institutes of Health, Bethesda, MD.

Cytokines in the Pathogenesis of Asthma and Th2-Mediated Diseases: *Regulation of CD4 Effector Cell Function in the Airway.*

2003: Symposium Speaker, North American Cystic Fibrosis Conference, Anaheim, CA. *Molecular Mechanisms of Goblet Cell Hyperplasia*.

2003: Physiology Seminar, Harvard School of Public Health, Cambridge, MA.

*Immune Dysregulation in Asthma: What Contributes to Th2 Cell Persistence?*

2003: Speaker, Novartis Foundation Symposium, Mucus Hypersecretion in Respiratory Disease, London, England.

*Cytokine Regulation of Mucus Hypersecretion in Models of Allergic Asthma.*

2003: Featured Speaker, American Thoracic Society, Atlanta, GA.

New Concepts of Immunity, Inflammation and Airway Remodeling in Asthma: *T Cells, Cytokines and the Pathway to Mucus Metaplasia*.

2003: Faculty, Post-Graduate Symposium, American Thoracic Society, Atlanta, GA. Assessment of Pulmonary Function in the Mouse.

# Professional Service

#### Peer Review Groups/Grant Study Sections

2009-2014 Reviewer, NIH, Center for Scientific Review, Special Emphasis Panels, 1-2 committees annually

2005-2009 American Lung Association, Research Training Fellowship Peer Review Committee

2008 Reviewer, NIH, Center for Scientific Review, Special Review Committee

2007 Reviewer, NIH, Center for Scientific Review, Special Emphasis Panel

2006 NIH, NHLBI, Initial Review Group

2004 NIH, NHLBI, Reviewer, Special Review Committee

2003 NIH, NHLBI, Reviewer, Special Review Committee

2002 NIH, NHLBI, Reviewer, Special Emphasis Panel

2001 NIH, NHLBI, Ad hoc Reviewer, Lung Biology and Pathology Study Section

1999 NIAID, Ad Hoc Reviewer, Special Emphasis Panel, Immunology Program Project Meeting

**Advisory Boards: lots more of these.**

2019 Sanofi-Regeneron

2018 Pieris, Astra-Zeneca, Sanofi-Regeneron, GSK,etc

2017 ATS Expert Panel (Astra Zeneca)

2015 Xolair Advisory Board (Genentech)

2014 Xolair Strategy Workshop (Novartis)

2014 Xolair Advisory Board (Genentech)

2001-2014 Mannkind Corporation: Data Safety Monitoring Board for Afrezza inhaled

insulin

1992-1993 Scientific Board of Directors

#### Journal Service:

Editor/Associate Editor

2008-present Editorial Board, *American Journal of Respiratory Cell and Molecular*

*Biology*

2009-2014 Editorial Board, *American Journal of Respiratory and Critical Care*

*Medicine*

2005-2008 Consulting Editor, *Journal of Clinical Investigation*

Reviewer

1998-present Reviewer for: *Journal of Clinical Investigation, Journal of Immunology, American Journal of Respiratory and Critical Care Medicine, American Journal of Respiratory Cell and Molecular Biology, Mucosal Immunology, Journal of Allergy and Clinical Immunology, Chest and others.*

**Professional Service for Professional Organizations:**

***American Thoracic Society***

2007-2008 Nominating Committee (elected), Allergy, Immunology and

Inflammation Assembly

2005-2006 Nominating Committee (elected), Allergy, Immunology and Inflammation Assembly

2001-2006 Program Committee, Allergy, Immunology and Inflammation Assembly

1993-present Member, Allergy, Immunology and Inflammation Assembly

**Yale University/Yale New Haven Hospital Service:**

2016-present Co-Chair, Yale New Haven Health Systems Population Health Clinical Integration Pulmonary Workgroup

2000-2013 Animal User’s Group

**BIBLIOGRAPHY:**

### **Peer-reviewed Original Research**

1. Ben-Nun A, Strauss W, Leeman S, **Cohn LE**, Murre C, Duby A, Seidman JG, Glimcher LH. An Ia positive mouse T cell clone is functional in presenting antigen to other T cells. *Immunogentics* 1985. 22:123-130.

2. **Cohn LE**, Glimcher LH, Waldmann RA, Smith JA, Ben-Nun A, Seidman JG, Choi E. Identification of functional regions on the I-Ab molecule by site directed mutagenesis. *Proc. Natl. Aca. Sci.* 1986. *USA* 83: 747-751.

3. Roman C, **Cohn LE**, Calame K. A dominant negative form of transcription activator mTFE3 created by differential splicing. *Science*. 1991. 254: 94-97.

4. Lederman S, Yellin M, Cleary A, Pernis A, Inghirami G, **Cohn LE**, Covey L, Lee J, Rothman P, Chess L. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death . *J. Immunol.* 1994. 152: 2163-71.

5. Zhang DH, **Cohn L**, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the IL-5 gene. *J. Biol. Chemistry* 1997. 272: 21597-21603.

6. **Cohn L**, Homer RJ, Marinov A, Rankin J, Bottomly K. Induction of airway mucus production by Th2 cells: A critical role for IL-4 in inflammation but not mucus production. *J. Exp. Med*. 1997. 186: 1737-1747.

7. **Cohn L**, Tepper JS, Bottomly K. IL-4 independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. 1998. *J. Immunol.* 161:3813-3816.

8. Yang L, **Cohn L**, Zhang DH, Homer R, Ray A, Ray P. Essential role of nuclear factor NF- in the induction of eosinophilia in allergic airway inflammation. *J. Exp. Med*. 1998. 188:1739-1750.

9. **Cohn L**, Homer R, MacLeod H, Mohrs M, Brombacher F, Bottomly K. Th2 induced airway mucus production is dependent on ILR, but not on eosinophils. *J. Immunol.* 1999. 162:6178-83.

10. Zhang DH, Yang L, **Cohn L**, Parkyn L, Homer R, Ray P, Ray A. Inhibition of allergic inflammation in a murine model of asthma by a expression of a dominant-negative mutant of GATA-3. *Immunity*. 1999. 11:473-482.

11. **Cohn L**, Homer R, Niu N, Bottomly K. Th1 cells and IFN- regulate allergic airway inflammation and mucus production. *J. Exp. Med.* 1999. 190:1309-1317.

12. Wang J, Homer RJ, Hong, L, **Cohn L**, Lee CG, Jung S, Elias JA. IL-11 selectively inhibits aeroallergen -induced pulmonary eosinophilia and Th2 cytokine production. *J. Immunol.* 2000. 165: 2222-2237.

13. Das J, Chen CH, Yang L, **Cohn L**, Ray P, Ray A. A critical role of NF- NF- in GATA3 expression and Th2 differentiation in allergic inflammation. *Nature Immunol*. 2001. 2:45-50.

14. **Cohn L**, Herrick C, Homer R, Niu N, Bottomly K. IL-4 promotes airway eosinophilia by suppressing IFN- production: defining a novel role for IFN- in the regulation of allergic airway inflammation. *J. Immunol*. 2001. 166:2760-2767.

15. Teder P, Vandivier RW, Jiang D, Liang J, **Cohn L**, Pure E, Henson PM, Noble P. Resolution of lung inflammation by CD44. *Science*. 2002. 296:155-158

16. Lee CG, Homer R, **Cohn L**, Link, H, Jung S, Craft J, Graham B, Johnson T, Elias J. Transgenic expression of IL-10 in the lung causes mucus metaplasia, tissue inflammation and airway remodelling via IL-13-dependent and -independent pathways. *J. Biol. Chem*. 2002. 277:35466-35474.

17. Whittaker L, Niu N, Temann A, Stoddard A, Flavell R, Ray A, Homer R, **Cohn L**. IL-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and IL-9. *Am. J. Respir. Cell Mol. Biol.* 2002. 27: 593-602.

18. Zhu Z, Zheng T, Homer RJ, Kim Y-K. Chen NY, **Cohn L**. Hamid Q, Elias JA. Essential role of acidic mammalian chitinase (AMCase) in asthmatic Th2 inflammation and IL-13 effector pathway activation. *Science*. 2004. 304:1678-1682.

19. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, **Cohn L**, Kim YK, McDonald DM and Elias JA. Vascular Endothelial Growth Factor (VEGF) Induces Parenchymal and Vascular Remodeling and Plays a Critical Role in Th2 Sensitization and Inflammation in the Lung. *Nature Medicine*. 2004. 10:1095-1103.

20. [Homer RJ, Zhu Z, **Cohn L**, Lee CG, White WI, Chen S, Elias JA.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract&list_uids=16556727&query_hl=1&itool=pubmed_docsum) Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. *Am. J. Physiol. Lung Cell. Mol. Physiol*. 2006. 291:L502-11

21. Zhang X, Shan P, Jiang G, **Cohn L**, Lee PJ. Toll-like receptor 4 deficiency causes pulmonary emphysema. *J. Clin. Invest.* 2006. 116: 3050–3059.

22. Allard JB, Poynter ME, Marr KA, **Cohn L,** Rincon M, Whittaker LA. Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. *J. Immunol.* 2006. 177:5186-5194.

23. Niu N, Le Goff MK, Li F, Rahman M, Homer RJ, **Cohn L**. A novel pathway that regulates inflammatory disease in the respiratory tract. *J. Immunol.* 2007. 178:3846-3855.

24. Simeone-Penney MC, Severgnini M, Tu P, Homer RJ, Mariani TJ, **Cohn L**, Simon AR. Airway epithelial STAT3 is required for allergic inflammation in a murine model of asthma. *J. Immunol.* 2007. 178:6191-6199.

25. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, **Cohn L**, Grusby MJ, Elias JA. IL-13 receptor-alpha2 selectively inhibits IL-13-induced responses in the murine lung. *J. Immunol.* 2008. 180:522-529.

26. Bessac BF, Sivula M, von Hehn CA, Escalera J, **Cohn L**, Jordt SE. TRPA1 is a major oxidant sensor in murine airway sensory neurons. *J. Clin. Invest.* 2008. 118:1899-1910.

27. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, **Cohn L**, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA. [Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL- 13-induced tissue responses and apoptosis.](http://www.ncbi.nlm.nih.gov/pubmed/19414556) *J Exp Med*. 2009. 206:1149-1166.

28. Oh SY, Zheng T, Kim YK, **Cohn L**, Homer RJ, McKenzie AN, Zhu Z. A Critical Role of SHP-1 in Regulation of Type 2 Inflammation in the Lung. 2009. *Am. J. Respir. Cell Mol. Biol.* 40:568-74.

29. Caceres AI, Brackmann M, Elia MD, Bessac BF, Del Camino D, D'Amours M, Witek JS, Fanger CM, Chong JA, Hayward NJ, Homer RJ, **Cohn L**, Huang X, Moran MM, Jordt SE. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. *Proc. Natl. Acad. Sci.* U. S. A. 2009. 106:9099-104.

30. Niu N, Laufer T, Homer RJ, **Cohn L**. Cutting Edge: Limiting MHC class II expression to DC alters the ability to develop Th2-dependent allergic airway inflammation. *J. Immunol*. 2009. 183: 1523-1527.

31. Chapoval SP, Lee CG, Tang C, Keegan AD, **Cohn L**, Bottomly K, Elias JA. Lung vascular endothelial growth factor expression induces local myeloid dendritic cell activation. *Clin. Immunol*. 2009. 132:371-84.

32. Wang Z, Kumamoto Y, Wang P, Gan X, Lehmann D, Smrcka AV, **Cohn L**, Iwasaki A, Li L, Wu D. Regulation of immature dendritic cell migration by a RhoA guanine nucleotide exchange factor ARHGEF5. *J. Biol. Chem*. 2009. 284: 28599-606

33. Wright PL, YU J, Di P, Homer RJ, Elias JA, **Cohn L**, Sessa,W. Epithelial reticulon-4B (Nogo-B) is an endogenous regulator of asthmatic inflammation. [*J. Exp. Med.*](javascript:AL_get(this,%20'jour',%20'J%20Exp%20Med.');) 2010. 207:2595-2607.

34. Mitchell C, Provost K,Niu N,Homer RJ, **Cohn L**. Interferon-gamma acts on the airway epithelium to inhibit local and systemic pathology in allergic airway disease. *J. Immunol.* *J. Immunol.* 2011. 187:3815-3820.

35. Britto CJ, Liu Q, Curran DR, Patham B, DelaCruz CS, **Cohn L**. SPLUNC1 is a tightly regulated airway sensor in innate and adaptive immunity*.*  *Am. J. Respir. Cell Mol. Biol.,* 2013. 48:717-724.

36. Takyar S, Vasavada H, Ahangari F, Lee CG, Liu Q, Niu N, **Cohn L**, Jack A Elias. [VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis.](http://www.ncbi.nlm.nih.gov/pubmed/24043765) *J. Exp. Med.* 2013. 210:1993-2010.

37. Yan X, Chu JH, Gomez J, Koenigs M, Holm C, [He X](http://www.ncbi.nlm.nih.gov/pubmed/?term=He%20X%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Perez MF](http://www.ncbi.nlm.nih.gov/pubmed/?term=Perez%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Zhao H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhao%20H%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Mane S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mane%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Martinez FD](http://www.ncbi.nlm.nih.gov/pubmed/?term=Martinez%20FD%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Ober C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ober%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Nicolae DL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nicolae%20DL%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Barnes KC](http://www.ncbi.nlm.nih.gov/pubmed/?term=Barnes%20KC%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [London SJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=London%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Gilliland F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gilliland%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Weiss ST](http://www.ncbi.nlm.nih.gov/pubmed/?term=Weiss%20ST%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Raby BA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Raby%20BA%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [**Cohn L**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cohn%20L%5BAuthor%5D&cauthor=true&cauthor_uid=25763605), [Chupp GL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chupp%20GL%5BAuthor%5D&cauthor=true&cauthor_uid=25763605). Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. *Am. J. Respir. Crit. Care Med*. 2015; 191(10):1116-25.

38. Gomez JL, Crisafi GM, Holm CT, Meyers DA, Hawkins GA, Bleecker ER, Jarjour N; Severe Asthma Research Program (SARP) Investigators, **Cohn L**, Chupp GL. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. *J. Allergy Clin. Immunol.* 2015; 136(1):51-58.

39. Yan X, Chu JH, Gomez J, Koenigs M, Holm C, He X, Perez MF, Zhao H, Mane S, Martinez FD, Ober C, Nicolae DL, Barnes KC, London SJ, Gilliland F, Weiss ST, Raby BA, **Cohn L**, Chupp GL. [Noninvasive Analysis of the Sputum Transcriptome Discriminates Clinical Phenotypes of Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/27027945) Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S104-5.

40. Nezgovorova V, Liu Q, Hu B, Villalobos JL, Yan X, Niu N, Holm C, Grant NP, Marone S, Ravage-Mass L, Lee CG, Elias JA, **Cohn L**, Chupp GL. [Sputum Gene Expression of IL-13 Receptor α2 Chain Correlates with Airflow Obstruction and Helper T-Cell Type 2 Inflammation in Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/27027964) Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S96-7.

41. Yan X, Liang A, Gomez J, **Cohn** L, Zhao H**,**Chupp GL. [A novel pathway-based distance score enhances assessment of disease heterogeneity in gene expression.](https://www.ncbi.nlm.nih.gov/pubmed/28637421) *BMC Bioinformatics*. 2017 Jun 20;18(1):309.

42. Chupp G, LavioletteM, **CohnL**, McEvoyC, Bansal S, ShifrenA, KhatriS, GrubbGM, McMullenE, Strauven R, KlineJN.Long term Outcomes of Bronchial Thermoplasty in Subjects with Severe Asthma: A Comparison of Three-Year Follow-Up Results from Two Prospective Multi-Center Studies. *Eur. Resp. J*. 2017 Oct 12;50(4):1750017

43. Gomez JL, Yan X, Holm CT, Grant N, Liu Q, **Cohn** L, Nezgovorova V, Meyers DA, Bleecker ER, Crisafi GM, Jarjour NN, Rogers L, Reibman J, Chupp GL; SARP Investigators. [Characterisation of asthma subgroups associated with circulating YKL-40 levels.](https://www.ncbi.nlm.nih.gov/pubmed/29025889) *Eur. Respir. J*. 2017 Oct 12;50(4):1700800.

44. Britto CJ, Niu N, Khanal S, HuleihelL, Herazo-Maya JD, ThompsonAM. SaulerM, SharmaM, Dela Cruz CS, KaminskiN, **Cohn L**. BPIFA1 Regulates Lung Neutrophil Recruitment and Interferon Signaling During Acute Inflammation. *Am. J. Physiol. Lung Cell Mol. Physiol.* 2019 Feb 1;316(2):L321-L333.

## **Chapters, Books, and Reviews**

1. Ray A and **Cohn L**. Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation *J. Clin. Invest.* 1999. 104:985-993.

2. Ray A and **Cohn L.** Altering the Th1/Th2 balance as a therapeutic strategy in asthmatic diseases. *Curr. Opinion Invest. Drugs*. 2000. 1:442-448.

3. **Cohn L** and Ray A. Th2-directed therapy for asthma. *Pharmacology and Therapeutics*. 2000. 88:187-196.

4. **Cohn L.** Perpective. Food for thought: Can immunological tolerance be induced to treat asthma? *Am. J. Respir. Cell Mol. Biol.* 2001. 24:509-512.

5. Whittaker LA and **Cohn L**. Recent concepts in the pathogenesis and treatment of asthma. *Clin. Pulm. Med.* 2002. 9: 135-144.

6. **Cohn L**, Whittaker L, Niu N, Homer R. Cytokine regulation of mucus production in a model of allergic asthma. In *Mucus Hypersecretion in Respiratory Disease*, Novartis Foundation Symposium. Wiley, Chichester, England. 2002. 248:201-13; discussion 213-20, 277-282.

7**. Cohn L** and Ray A. Biology of lymphocytes, In *Middleton's Allergy: Principles and Practice* ed 6, Mosby, St. Louis, MO. 2003. 279-290.

8. **Cohn L,** Elias JA, Chupp GL. Asthma: Mechanisms of disease persistence and progression. *Annu. Rev Immunol.* 2004. 22: 789-815.

9. **Cohn L.** Mucus in chronic airway diseases: Sorting out the sticky details. *J. Clin.Invest*. 2006. 116:306-308.

10**. Cohn L** and Ray A. Chapter 16: Biology of Lymphocytes, *in Middleton's Allergy: Principles and Practice* ed 7, Mosby, St. Louis, MO. 2009. 271-282.

11. **Cohn, L.** Mechanisms of Mucus Induction in Asthma. In *Allergy Frontiers: Clinical Manifestations.* Editors: Panawankar R, Holgate S and Rosenwasser L. Springer, Tokyo, Japan. 2009. 173-185.

12. Curran DR and **Cohn L.** Advances in Mucous Cell Metaplasia: A Plug for Mucus as a Therapeutic Focus in Chronic Airway Disease, *Am. J. Respir. Cell Mol. Biol*. 2010. 42: 268-275.

13**. Cohn L**, Hawrylowicz C, Ray A Chapter 12: Biology of Lymphocytes, in *Middleton's Allergy: Principles and Practice* ed 8. Elsevier. Philadelphia, PA. 2014. 203-214.

14**. Cohn L** and Woodruff P. Update in Asthma 2013. *Am. J. Respir. Crit. Care Med*. 2014. 189:1487-1493.

15. Britto, C and **Cohn L**. BPIFA1 (SPLUNC1) in host protection and respiratory disease. *Am. J. Respir. Cell Mol. Biol.* 2015. 52:525-34.

16. **Cohn L.** T lymphocytes in the Lung. Grippi M, Elias J, Fishman J, et al. *Fishman’s Pulmonary Diseases and Disorders, 5th ed.* New York: McGraw-Hill, 2015, 318-326.

17. Camiolo M, Gauthier M, Cohn L, Ray A. Chapter 12: Biology of Lymphocytes, in *Middleton's Allergy: Principles and Practice* ed 9. *In Press.*